IFIT3 and hematologic disorder: Various studies suggest that IFIT3 might serve as a clinical biomarker in OSCC [16,26,72], lung cancer [73], gastrointestinal tract [50,74,75] and hematological malignancies [36,76], melanoma [20], breast [77], bladder [78] and thyroid [79] and other cancers.